MCA
GSK icon

MSH Capital Advisors’s GSK GSK Stock Holding History

MSH Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,224
Closed -$254K – 229
2024
Q3 		$254K Sell
6,224
-181
-3% -$7.41K 0.08% 205
2024
Q2 		$247K Sell
6,405
-519
-7% -$21.8K 0.08% 201
2024
Q1 		$297K Sell
6,924
-824
-11% -$34K 0.1% 175
2023
Q4 		$287K Sell
7,748
-536
-6% -$19.2K 0.11% 169
2023
Q3 		$300K Hold
8,284
– – 0.12% 169
2023
Q2 		$295K Sell
8,284
-300
-3% -$10.8K 0.11% 178
2023
Q1 		$305K Sell
8,584
-240
-3% -$8.4K 0.13% 159
2022
Q4 		$310K Sell
8,824
-520
-6% -$17.3K 0.14% 149
2022
Q3 		$275K Buy
9,344
+19
+0.2% +$720 0.14% 155
2022
Q2 		$507K Sell
9,325
-480
-5% -$26.5K 0.24% 106
2022
Q1 		$534K Buy
9,805
+436
+5% +$23.7K 0.22% 106
2021
Q4 		$516K Buy
+9,369
New +$487K 0.23% 102

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MSH Capital Advisors's GSK Position: Q4 2024 in Review

MSH Capital Advisors sold out of GSK (GSK) in Q4 2024, closing a stake of 6,224 shares — an estimated $254K sold.

MSH Capital Advisors first reported a position in GSK in Q4 2021 and held it in 12 quarters. The position peaked at $534K in Q1 2022. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

  • MSH Capital Advisors reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
  • MSH Capital Advisors sold 6,224 GSK shares in Q4 2024, an estimated $254K.
  • MSH Capital Advisors first reported a position in GSK in Q4 2021 and held it in 12 quarters.
  • MSH Capital Advisors's GSK position peaked at $534K in Q1 2022.
  • 848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on MSH Capital Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.